Animal models of Huntington’s disease and their applicability to novel drug discovery and development

References

• Georgiou-Karistianis N, Egan GF, Egan GF. Connectivity-based segmentation of the striatum in Huntington’s disease: vulnerability of motor pathways. Neurobiol Dis. 2011;42(3):475–481.
   PubMedGoogle Scholar
• Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodegener Dis Manag. 2016;6(4):331–343.
   PubMed Web of Science ®Google Scholar
• Ament SA, Pearl JR, Grindeland A, et al. High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington’s disease CAG knock-in mice across multiple genetic backgrounds. Hum Mol Genet. 2017;26(5):913–922. DOI:10.1093/hmg/ddx006
   PubMedGoogle Scholar
• Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–1091. DOI:10.1002/mds.25075
   PubMed Web of Science ®Google Scholar
• Claassen DO, Ayyagari R, Garcia-Horton V, et al. Real-world adherence to tetrabenazine or deutetrabenazine among patients with huntington’s disease: a retrospective database analysis. Neurol Ther. 2022;11(1):435–448. DOI:10.1007/s40120-021-00309-5
   PubMedGoogle Scholar
• Maehle A-H. Animal experimentation from antiquity to the end of the eighteenth century: attitudes and arguments. In: Rupke A, editor. Vivisection in historical perspective. London: Croom Helm; 1987. p. 14–47.
   Google Scholar
• Davidson M, Lindsey J, Davis J. Requirements and selection of an animal model. Isr J Med Sci. 1987;23(6):551–555.
   PubMedGoogle Scholar
• Rand MS. Selection of biomedical animal models. In: Conn PM, editor. Sourcebook of models for biomedical research. Totowa, NJ: Humana Press; 2008. p. 9–15.
   Google Scholar
• Singh VK, Seed TM. How necessary are animal models for modern drug discovery? Expert Opin Drug Discov. 2021;16(12):1391–1397.
   PubMedGoogle Scholar
• Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci. 2013;14(10):708–721.
   PubMedGoogle Scholar
• Freires IA, Sardi J, de Castro RD, et al. Alternative animal and non-animal models for drug discovery and development: bonus or burden? 11. Pharm Res. 2017;34(4):681–686. DOI:10.1007/s11095-016-2069-z
   PubMed Web of Science ®Google Scholar
• Neri C. Value of invertebrate genetics and biology to develop neuroprotective and preventive medicine in Huntington’s disease. In: Lo DC, Hughes RE, editor. Neurobiology of Huntington’s disease: applications to drug discovery. Boca Raton: CRC Press/Taylor & Francis; 2011. p. 1–39.
   Google Scholar
• Hobert O. Neurogenesis in the nematode Caenorhabditis elegans. WormBook: the online review of C. Elegans Biology. 2018;1–24. DOI:10.1895/wormbook.1.161.1
   Google Scholar
• Parker JA, Metzler M, Georgiou J, et al. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. J Neurosci. 2007;27(41):11056–11064. DOI:10.1523/JNEUROSCI.1941-07.2007
   PubMedGoogle Scholar
• Rudich P, Lamitina T. Models and mechanisms of repeat expansion disorders: a worm’s eye view. J Genet. 2018;97(3):665–677.
   PubMedGoogle Scholar
• Ma L, Zhao Y, Chen Y, et al. Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases. Eur J Pharmacol. 2018;819:169–180.
   PubMedGoogle Scholar
• Cordeiro LM, Soares MV, da Silva AF, et al. Neuroprotective effects of rutin on ASH neurons in Caenorhabditis elegans model of Huntington’s disease. Nutr Neurosci. 2021;25(11):2288–2301.
   Google Scholar
• Bicca Obetine Baptista F, Arantes LP, Machado ML, et al. Diphenyl diselenide protects a Caenorhabditis elegans model for Huntington’s disease by activation of the antioxidant pathway and a decrease in protein aggregation. Metallomics. 2020;12(7):1142–1158. DOI:10.1039/d0mt00074d
   PubMed Web of Science ®Google Scholar
• Boasquívis PF, Silva GMM, Paiva FA, et al. Guarana (Paullinia cupana) extract protects Caenorhabditis elegans models for Alzheimer disease and Huntington disease through activation of antioxidant and protein degradation pathways. Oxid Med Cell Longev. 2018;16: 1–16. 9241308. DOI:10.1155/2018/9241308
   Google Scholar
• Zhang J, Shi R, Li H, et al. Antioxidant and neuroprotective effects of Dictyophora indusiata polysaccharide in Caenorhabditis elegans. J Ethnopharmacol. 2016;192:413–422.
   PubMed Web of Science ®Google Scholar
• Zhang S, Feany MB, Saraswati S, et al. Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington’s disease model. Dis Model Mech. 2009;2(5–6):247–266. DOI:10.1242/dmm.000653
   PubMed Web of Science ®Google Scholar
• Donnelly KM, Pearce MM. Monitoring cell-to-cell transmission of prion-like protein aggregates in Drosophila melanogaster. JoVe. 2018;133:e56906. DOI:10.3791/56906
   Google Scholar
• Lewis EA, Smith GA. Using Drosophila models of Huntington’s disease as a translatable tool. J Neurosci Methods. 2016;265:89–98.
   PubMedGoogle Scholar
• Lin Y-H, Maaroufi HO, Ibrahim E, et al. Expression of human mutant huntingtin protein in Drosophila hemocytes impairs immune responses. Front Immunol. 2019;10:2405.
   PubMedGoogle Scholar
• Smith MR, Syed A, Lukacsovich T, et al. A potent and selective sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum Mol Genet. 2014;23(11):2995–3007. DOI:10.1093/hmg/ddu010
   PubMed Web of Science ®Google Scholar
• Casale AM, Liguori F, Ansaloni F, et al. Transposable element activation promotes neurodegeneration in a Drosophila model of Huntington’s disease. Iscience. 2022;25(1):103702. DOI:10.1016/j.isci.2021.103702
   PubMedGoogle Scholar
• Arabit JG, Elhaj R, Schriner SE, et al. Rhodiola rosea improves lifespan, locomotion, and neurodegeneration in a Drosophila melanogaster model of Huntington’s disease. BioMed Res Int. 2018;2018:1–8.
   Google Scholar
• Xiao L, Li H, Zhang J, et al. Salidroside protects Caenorhabditis elegans neurons from polyglutamine-mediated toxicity by reducing oxidative stress. Molecules. 2014;19(6):7757–7769. DOI:10.3390/molecules19067757
   PubMed Web of Science ®Google Scholar
• Delfino L, Mason RP, Kyriacou CP, et al. Rab8 promotes mutant HTT aggregation, reduces neurodegeneration, and ameliorates behavioural alterations in a Drosophila model of Huntington’s disease. J Huntington’s Dis. 2020;9(3):253–263. DOI:10.3233/JHD-200411
   PubMedGoogle Scholar
• Das S, Rajanikant G. Huntington disease: can a zebrafish trail leave more than a ripple? Neurosci Biobehav Rev. 2014;45:258–261.
   PubMedGoogle Scholar
• Vaz RL, Outeiro TF, Ferreira JJ. Zebrafish as an animal model for drug discovery in Parkinson’s disease and other movement disorders: a systematic review. Front Neurol. 2018;9:347.
   PubMedGoogle Scholar
• Veldman MB, Rios-Galdamez Y, X-H L, et al. The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model. Mol Neurodegener. 2015;10(1):1–16. DOI:10.1186/s13024-015-0063-2
   PubMedGoogle Scholar
• Diekmann H, Anichtchik O, Fleming A, et al. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J Neurosci. 2009;29(5):1343–1349. DOI:10.1523/JNEUROSCI.6039-08.2009
   PubMedGoogle Scholar
• Sager JJ, Bai Q, Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct. 2010;214(2–3):285–302.
   PubMed Web of Science ®Google Scholar
• Xi Y, Noble S, Ekker M. Modeling neurodegeneration in zebrafish. Curr Neurol Neurosci Rep. 2011;11(3):274–282.
   PubMed Web of Science ®Google Scholar
• Gama Sosa MA, De Gasperi R, Elder GA. Modeling human neurodegenerative diseases in transgenic systems. Hum Genet. 2012;131(4):535–563.
   PubMed Web of Science ®Google Scholar
• Conforti P, Zuccato C, Gaudenzi G, et al. Binding of the repressor complex REST‐mSIN 3b by small molecules restores neuronal gene transcription in Huntington’s disease models. J Neurochem. 2013;127(1):22–35. DOI:10.1111/jnc.12348
   PubMed Web of Science ®Google Scholar
• Kumar V, Singh A. Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: an opinion. Excli J. 2021;20:1086.
   PubMedGoogle Scholar
• Kumar P, Kalonia H, Kumar A. Huntington’s disease: pathogenesis to animal models. Pharmacol Rep. 2010;62(1):1–14.
   PubMed Web of Science ®Google Scholar
• Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Sci OA. 2015;1(4):1–3. DOI:10.4155/fso.15.63
   Google Scholar
• Hervás-Corpión I, Guiretti D, Alcaraz-Iborra M, et al. Early alteration of epigenetic-related transcription in Huntington’s disease mouse models. Sci Rep. 2018;8(1):1–14. DOI:10.1038/s41598-018-28185-4
   PubMedGoogle Scholar
• Dabrowska M, Ciolak A, Kozlowska E, et al. Generation of new isogenic models of Huntington’s disease using CRISPR-Cas9 technology. Int J Mol Sci. 2020;21(5):1854. DOI:10.3390/ijms21051854
   PubMedGoogle Scholar
• Ekman FK, Ojala DS, Adil MM, et al. CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington’s disease mouse model. Mol Ther Nucleic Acids. 2019;17:829–839.
   PubMedGoogle Scholar
• Suelves N, Miguez A, López-Benito S, et al. Early downregulation of p75NTR by genetic and pharmacological approaches delays the onset of motor deficits and striatal dysfunction in Huntington’s disease mice. Mol Neurobiol. 2019;56(2):935–953. DOI:10.1007/s12035-018-1126-5
   PubMedGoogle Scholar
• Lu AT, Narayan P, Grant MJ, et al. DNA methylation study of Huntington’s disease and motor progression in patients and in animal models. Nat Commun. 2020;11(1):1–15. DOI:10.1038/s41467-020-18255-5
   PubMedGoogle Scholar
• Agrawal S, Fox JH. Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington’s disease. Mitochondrion. 2019;47:318–329.
   PubMedGoogle Scholar
• Kurat S, Heinrich P, Molnar-Kasza A, et al. Homozygosity of BACHD rats not only causes strong behavioral deficits in young female rats but also a reduced breeding success. Brain Res. 2021;1761:147396.
   PubMedGoogle Scholar
• Southwell AL, Skotte NH, Kordasiewicz HB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22(12):2093–2106. DOI:10.1038/mt.2014.153
   PubMed Web of Science ®Google Scholar
• Datson NA, González-Barriga A, Kourkouta E, et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE. 2017;12:e0171127.
   PubMed Web of Science ®Google Scholar
• Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–474. DOI:10.1089/hum.2013.200
   PubMed Web of Science ®Google Scholar
• Suganya SN, Sumathi T. Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington’s disease model in rats. Metab Brain Dis. 2017;32(2):471–481.
   PubMed Web of Science ®Google Scholar
• Mishra J, Kumar A. Improvement of mitochondrial NAD+/FAD±linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington’s disease. Pharmacol Rep. 2014;66(6):1148–1155.
   PubMedGoogle Scholar
• Underwood BR, Imarisio S, Fleming A, et al. Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum Mol Genet. 2010;19(17):3413–3429. DOI:10.1093/hmg/ddq253
   PubMed Web of Science ®Google Scholar
• Yuan C, Zheng L, Zhao Y. Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats. Biomed Pharmacother. 2022;155:113664.
   PubMedGoogle Scholar
• Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington’s disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol. 2009;615(1–3):91–101. DOI:10.1016/j.ejphar.2009.04.058
   PubMed Web of Science ®Google Scholar
• Navrotskaya V, Oxenkrug G. Effect of kynurenic acid on development and aging in wild type and vermilion mutants of Drosophila melanogaster. Pharmacol Drug Dev Ther. 2016;1(1):1–7.
   Google Scholar
• Kumar P, Padi SSV, Naidu PS, et al. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006;17(5–6):485–492. DOI:10.1097/00008877-200609000-00014
   PubMedGoogle Scholar
• Kalonia H, Kumar P, Kumar A. Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats. Eur J Pharmacol. 2010;634(1–3):46–52.
   PubMedGoogle Scholar
• Ramachandran S, Thangarajan S. Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington’s disease. Metab Brain Dis. 2018;33(5):1459–1470.
   PubMedGoogle Scholar
• Menze ET, Esmat A, Tadros MG, et al. Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties. PLoS ONE. 2015;10(2):e0117223. DOI:10.1371/journal.pone.0117223
   PubMed Web of Science ®Google Scholar
• Mustafa AM, Rabie MA, Zaki HF, et al. Inhibition of brain GTP cyclohydrolase i attenuates 3-Nitropropionic acid-induced striatal toxicity: involvement of mas receptor/PI3k/Akt/CREB/BDNF axis. Front Pharmacol. 2021;12. DOI:10.3389/fphar.2021.740966
   Google Scholar
• Gopinath K, Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neurosci J. 2012;227:134–143.
   Google Scholar
• Bansal PK, Deshmukh R. Animal models of neurological disorders: principle and working procedure for animal models of neurological disorders. Springer Nature Singapore. 2018;1:1–343.
   Google Scholar
• Chidambaram SB, Vijayan R, Sekar S, et al. Simultaneous blockade of NMDA receptors and PARP-1 activity synergistically alleviate immunoexcitotoxicity and bioenergetics in 3-nitropropionic acid intoxicated mice: evidences from memantine and 3-aminobenzamide interventions. Eur J Pharmacol. 2017;803:148–158.
   PubMedGoogle Scholar
• Coyle JT, Schwarcz R. Lesion of striatal neurons with kainic acid provides a model for Huntington’s chorea. Nature. 1976;263(5574):244–246. DOI:10.1038/263244a0
   PubMedGoogle Scholar
• Jamwal S, Kumar P. Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: possible role of oxidative stress, neuroinflammation, and neurotransmitters. Physiol Behav. 2016;155:180–187.
   PubMedGoogle Scholar
• Bondulich MK, Fan Y, Song Y, et al. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease. Sci Rep. 2021;11(1):1–18. DOI:10.1038/s41598-021-84858-7
   PubMedGoogle Scholar
• Spronck EA, Vallès A, Lampen MH, et al. Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology. Brain Sci. 2021;11(2):129. DOI:10.3390/brainsci11020129
   PubMed Web of Science ®Google Scholar
• Clemens LE, Weber JJ, Wlodkowski TT, et al. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Brain. 2015;138(12):3632–3653. DOI:10.1093/brain/awv290
   PubMedGoogle Scholar
• Singh S, Jamwal S, Kumar P. Piperine enhances the protective effect of curcumin against 3-NP induced neurotoxicity: possible neurotransmitters modulation mechanism. Neurochem Res. 2015;40(8):1758–1766.
   PubMed Web of Science ®Google Scholar
• Torabi A, Joneidi M, Mohammadzadeh I, et al. The effect of 3-nitropropionic acid on behavioral dysfunction, neuron loss and gliosis in the brain of adult male rats: the case of prefrontal cortex, hippocampus and the cerebellum. Toxicon. 2020;183:44–50.
   PubMedGoogle Scholar
• Torres‐cruz FM, Mendoza E, Vivar‐cortés IC, et al. Do BDNF and NT‐4/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington’s disease? J Neuro Res. 2019;97:1665–1677.
   PubMedGoogle Scholar
• Stepanova P, Srinivasan V, Lindholm D, et al. Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington’s disease. Sci Rep. 2020;10(1):1–12. DOI:10.1038/s41598-020-75439-1
   PubMedGoogle Scholar
• Kovalenko M, Milnerwood A, Giordano J, et al. Htt Q111/+ Huntington’s disease knock-in mice exhibit brain region-specific morphological changes and synaptic dysfunction. J Huntington’s Dis. 2018;7(1):17–33. DOI:10.3233/JHD-170282
   PubMedGoogle Scholar
• Morton AJ, Howland DS. Large genetic animal models of Huntington’s disease. J Huntington’s Dis. 2013;2(1):3–19. DOI:10.3233/JHD-130050
   PubMedGoogle Scholar
• Handley R, Reid SJ, Patassini S, et al. Metabolic disruption identified in the Huntington’s disease transgenic sheep model. Sci Rep. 2016;6(1):1–11. DOI:10.1038/srep20681
   PubMedGoogle Scholar
• Morton A. Large-brained animal models of huntington’s disease: sheep. In: Precious S, Rosser A Dunnett S, editors. Huntington’s disease. methods in molecular biology. Vol. 1780. New York (NY): Humana Press; 2018. p. 221–239.
   Google Scholar
• Handley RR, Reid SJ, Brauning R, et al. Brain urea increase is an early Huntington’s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases. Proc Natl Acad Sci. 2017;114(52):E11293–11302. DOI:10.1073/pnas.1711243115
   PubMed Web of Science ®Google Scholar
• Laowtammathron C, Cheng EC, Cheng P-H, et al. Monkey hybrid stem cells develop cellular features of Huntington’s disease. BMC Cell Biol. 2010;11(1):1–12. DOI:10.1186/1471-2121-11-12
   PubMedGoogle Scholar
• Snyder BR, Chan AW. Progress in developing transgenic monkey model for Huntington’s disease. J Neural Transm. 2018;125(3):401–417.
   PubMedGoogle Scholar
• Yan S, Tu Z, Liu Z, et al. A Huntingtin knockin pig model recapitulates features of selective neurodegeneration in Huntington’s disease. Cell. 2018;173(4):989–1002. e13. DOI:10.1016/j.cell.2018.03.005
   PubMed Web of Science ®Google Scholar
• Yang D, Wang C-E, Zhao B, et al. Expression of Huntington’s disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet. 2010;19(20):3983–3994. DOI:10.1093/hmg/ddq313
   PubMedGoogle Scholar
• Klonarakis M, De Vos M, Woo E, et al. The three sisters of fate: genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases. Neuro sci Biobehav Rev. 2022;135:104541.
   PubMedGoogle Scholar
• Wang C-E, Tydlacka S, Orr AL, et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Hum Mol Genet. 2008;17(17):2738–2751. DOI:10.1093/hmg/ddn175
   PubMedGoogle Scholar
• Baxa M, Levinska B, Skrivankova M, et al. Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington’s disease. Dis Model Mech. 2020;13:dmm041293.
   Google Scholar
• Sams-Dodd F. Strategies to optimize the validity of disease models in the drug discovery process. Drug Discov Today. 2006;11(7–8):355–363.
   PubMedGoogle Scholar
• Denayer T, Stöhr T, Van Roy M. Animal models in translational medicine: validation and prediction. New Horiz Transl. 2014;2(1):5–11. DOI:10.1016/j.nhtm.2014.08.001
   Google Scholar
• Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord. 2011;1(1):1–14.
   PubMedGoogle Scholar
• Geyer MA, Markou A. Animal models of psychiatric disorders. In: Floyd E, and Kupfer David J, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 787–798.
   Google Scholar
• McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol. 2014;87(1):162–171.
   PubMed Web of Science ®Google Scholar
• van Wamelen DJ, Aziz NA, Roos RA, et al. Hypothalamic alterations in Huntington’s disease patients: comparison with genetic rodent models. J Neuroendocrinol. 2014;26(11):761–775. DOI:10.1111/jne.12190
   PubMedGoogle Scholar
• Wiprich MT, Zanandrea R, Altenhofen S, et al. Influence of 3-nitropropionic acid on physiological and behavioral responses in zebrafish larvae and adults. Comp Biochem Physiol C Toxicol Pharmacol. 2020;234:108772.
   PubMedGoogle Scholar
• Dash D, Mestre TA. Therapeutic update on huntington’s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics. 2020;17(4):1645–1659.
   PubMedGoogle Scholar
• Kumar A, Kumar V, Singh K, et al. Therapeutic advances for Huntington’s disease. Brain Sci. 2020;10(1):43. DOI:10.3390/brainsci10010043
   PubMed Web of Science ®Google Scholar
• Ryskamp D, Wu J, Geva M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97:46–59.
   PubMed Web of Science ®Google Scholar
• Zhemkov V, Geva M, Hayden MR, et al. Sigma-1 receptor (S1R) Interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases. Int J Mol Sci. 2021;22(8):4082. DOI:10.3390/ijms22084082
   PubMed Web of Science ®Google Scholar
• Asla MM, Nawar AA, Abdelsalam A, et al. The efficacy and safety of pridopidine on treatment of patients with huntington’s disease: a systematic review and meta-analysis. Mov Disord Clin Pract. 2022;9(1):20–30. DOI:10.1002/mdc3.13357
   PubMed Web of Science ®Google Scholar
• Chen S, Liang T, Xue T, et al. Pridopidine for the improvement of motor function in patients with huntington’s disease: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2021;12:658123.
   PubMedGoogle Scholar
• Kim A, Lalonde K, Truesdell A, et al. New avenues for the treatment of Huntington’s disease. Int J Mol Sci. 2021;22(16):8363. DOI:10.3390/ijms22168363
   PubMedGoogle Scholar
• Ségalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem Biol. 2007;2(4):231–236.
   PubMed Web of Science ®Google Scholar
• Travessa AM, Rodrigues FB, Mestre TA, et al. Fifteen years of clinical trials in Huntington’s disease: a very low clinical drug development success rate. J Huntington’s Dis. 2017;6(2):157–163. DOI:10.3233/JHD-170245
   PubMedGoogle Scholar
• Braz BY, Wennagel D, Ratié L, et al. Treating early postnatal circuit defect delays Huntington’s disease onset and pathology in mice. Science. 2022;377(6613):eabq5011. DOI:10.1126/science.abq5011
   PubMedGoogle Scholar
• Rodríguez-Urgellés E, Rodríguez-Navarro I, Ballasch I, et al. Postnatal foxp2 regulates early psychiatric-like phenotypes and associated molecular alterations in the R6/1 transgenic mouse model of Huntington’s disease. Neurobiol Dis. 2022;173:105854.
   PubMedGoogle Scholar
• L Burrows E, J Hannan A. Towards environmental construct validity in animal models of CNS disorders: optimizing translation of preclinical studies. CNS Neurol Disord - Drug Targ. 2013;12(5):587–592. DOI:10.2174/1871527311312050007
   PubMedGoogle Scholar